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Sterol regulatory element binding proteins (SREBPs) are a family of transcription factors that
regulate lipid biosynthesis and adipogenesis by controlling the expression of several enzymes
required for cholesterol, fatty acid, triacylglycerol and phospholipid synthesis. In vertebrates,
SREBP activation is mainly controlled by a complex and well-characterized feedback
mechanism mediated by cholesterol, a crucial bio-product of the SREBP-activated mevalonate
pathway. In this work, we identified acto-myosin contractility and mechanical forces imposed
by the extracellular matrix (ECM) as SREBP1 regulators. SREBP1 control by mechanical cues
depends on geranylgeranyl pyrophosphate, another key bio-product of the mevalonate
pathway, and impacts on stem cell fate in mouse and on fat storage in Drosophila.
Mechanistically, we show that activation of AMP-activated protein kinase (AMPK) by ECM
stiffening and geranylgeranylated RhoA-dependent acto-myosin contraction inhibits SREBP1
activation. Our results unveil an unpredicted and evolutionary conserved role of SREBP1 in
rewiring cell metabolism in response to mechanical cues.
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Conserved from yeast to humans, SREBPs are transcriptionfactors which function as master regulators of genes thatcontrol cellular lipid homoeostasis to meet organismal
requirements1. SREBPs have been shown to play key roles in
coupling lipid metabolism with nutrition, cell growth, energy
stress, inflammation and other physiological and pathological
processes2. In vertebrates, SREBP1 and SREBP2 proteins trans-
locate from the endoplasmic reticulum to the Golgi apparatus, in
response to deprivation of cholesterol. Then they are processed by
proteolytic cleavage and targeted to the nucleus, where they
induce the expression of genes mainly involved in sterol and fatty
acid biosynthesis3.
The complex function of SREBP proteins implicates a fine-tuning
of their activity at multiple levels. In addition to mechanisms that
control the stability of SREBP proteins through a complex reper-
toire of post-translational modifications (PTMs), negative feedback
loops by the end products of the SREBP pathway play a key role in
regulating SREBP activation2. While SREBP translocation and
proteolytic maturation mechanisms are widely conserved, the auto-
regulatory systems show differences among species4. For example,
SREBP activity is primarily sensitive to phospholipids in Drosophila
melanogaster and Caenorhabditis elegans, which are cholesterol
auxotrophs. Conversely, SREBP activity is primarily sensitive to
sterols in vertebrates, though SREBP1 maturation has been shown
to be sensitive to some polyunsaturated fatty acids (PUFAs) in
human cells, independently of cholesterol5.
In addition to sterols, the SREBP-induced mevalonate pathway
produces key isoprenoid metabolites, farnesyl pyrophosphate
(FPP) and geranylgeranyl pyrophosphate (GGPP), which serve as
lipid donors for regulatory PTMs of target proteins (prenylation)6.
Inhibition of SREBPs, by reducing the levels of isoprenoids,
impacts on a plethora of biological processes, including cell divi-
sion, migration, death, intracellular trafficking, protein stability
and cytoskeleton organization7. Deregulation of isoprenoid levels
and protein prenylation is involved in many pathological condi-
tions such as neurodegeneration, cardiovascular diseases and
cancer6,8–10. Despite their crucial activity as pathophysiological
effectors of SREBPs, the role of isoprenoids in the regulation of
SREBP activation has been poorly investigated so far.
Here we demonstrate that acto-myosin contraction, down-
stream of RhoA prenylation, controls SREBP1 function, a
mechanism conserved from Drosophila to human that links
extracellular matrix (ECM) mechanical cues to lipid metabolism.
Mechanistically we find that, in response to ECM rigidity, the
energy sensor AMP-activated protein kinase (AMPK) inhibits
SREBP1 activation, which impacts on physiological and patho-
physiological processes such as mesenchymal stem cell (MSC)
differentiation and tissue fibrosis.
Results
Protein geranylgeranylation controls SREBP1 transcriptional
activity. To investigate whether isoprenoids play a role in the
activation of SREBPs, human epithelial breast cell lines were
transfected with two reporter plasmids, low density lipoprotein
promoter-luciferase (LDLR-Luc)11 and Steaoryl-CoA desaturase
promoter-luciferase (SCD1-Luc), as readouts of SREBP activation
and were maintained in conditions of reduced intracellular cho-
lesterol in order to activate SREBPs. Specifically, cells were treated
with cerivastatin, or grown in serum-free or lipid-depleted media.
All these conditions induced a robust activation of SREBPs, as
demonstrated by increased luciferase activity after 24 h, using
either LDLR-Luc (Fig. 1a) or SCD1-Luc (Supplementary Fig. 1a).
As expected, supplementing the medium with cholesterol pre-
vented SREBP activation (Fig. 1a and Supplementary Fig. 1a).
Interestingly, addition of GGPP to the medium, but not of FPP,
inhibited SREBP activation to an extent comparable to cholesterol
addition (Fig. 1a and Supplementary Fig. 1a). These results were
confirmed by analysing the expression in serum-starved cells of
four endogenous SREBP target genes, LDLR, SCD1, Acetyl-CoA
Carboxylase 1 (ACC1) and Fatty Acid Synthase (FASN) at the
mRNA levels (Fig. 1b), and of SCD1 protein level (Fig. 1c). The
processing of SREBP1 was strongly prevented by GGPP in serum-
starved cells after 24 h of treatment, while under the same con-
ditions SREBP2 processing remained unaltered (Fig. 1c). To
completely deprive cells of cholesterol, both exogenously uptaken
and endogenously synthetized, cells were maintained in lipid-
depleted medium and treated with statin. In these conditions,
GGPP addition prevented activation of LDLR-Luc (Fig. 1d) and
SCD1-Luc (Supplementary Fig. 1b), upregulation of LDLR, SCD1,
ACC1 and FASN mRNA (Supplementary Fig. 1c), of SCD1
protein (Supplementary Fig. 1d), and processing of SREBP1
(Supplementary Fig. 1d). This result clearly demonstrates that the
effect of GGPP was independent of cholesterol.
The effect of GGPP on SREBP1 processing was further
confirmed in a panel of cell lines from different tissues, as breast
(MDA-MB 231), lung (H1299) and liver (Mahlavu and
Immortalized Human Hepatocytes, namely IHH) (Supplemen-
tary Fig. 1e, f). In line with these results, GGPP treatment
prevented SREBP1 nuclear translocation induced by serum
starvation (Supplementary Fig. 1g). Altogether, these results
establish GGPP, a key intermediate of the mevalonate pathway, as
an endogenous modulator of SREBP1 maturation and function.
Upon binding to geranylgeranyl-transferase 1 (GGTI, hereafter
referred to as GGTase1), GGPP modifies a considerable number
of target proteins (Fig. 1e) mainly involved in signal transduction,
structural organization and trafficking, controlling their localiza-
tion and function6. To test whether protein geranylgeranylation
was involved in SREBP1 activation, we inhibited the transfer of
the geranylgeranyl moiety to target proteins by using GGTI-298,
a specific inhibitor of GGTase19. This treatment induced a strong
activation of SREBP1 transcriptional activity, as assessed using
the LDLR-Luc (Fig. 1f and Supplementary Fig. 1h) and SCD1-Luc
(Supplementary Fig. 1i) reporters. This effect was specific since a
mutation of a single nucleotide within the sterol responsive
element (SRE) of the LDLR-Luc reporter construct completely
prevented the luciferase signal (Fig. 1f). GGTI-298 treatment also
caused a robust and time-dependent increase of SREBP1
maturation (Fig. 1g and Supplementary Fig. 1k), with a
consequent induction of SREBP1 target genes, as monitored by
upregulation of SCD1 mRNA (Fig. 1h and Supplementary Fig. 2l)
and protein (Fig. 1g and Supplementary Fig. 1k) levels, and
upregulation of LDLR, ACC1, FASN, and 3-hydroxy-3-methylglu-
taryl-CoA reductase (HMGCR) mRNA levels (Fig. 1h, Supple-
mentary Fig. 1j and Supplementary Fig. 2l). This effect was
prevented by SREBP1 knockdown (Fig. 1i and Supplementary
Fig. 1l). SREBP1 activation upon GGTI-298 treatment also
increased the intracellular content of lipids, with a consequent
accumulation of lipid droplets within the cytoplasm (Fig. 1j).
Under these conditions, adding back GGPP did not reverse
SREBP1 activation (Supplementary Fig. 1m), suggesting that
protein prenylation, instead of the GGPP intracellular levels, is
required for SREBP1 regulation.
Taken together, these data demonstrate that SREBP1 is
controlled by protein geranylgeranylation and suggest that one
or more GGTase1 target proteins are involved in SREBP1
activation and lipid biosynthesis.
Evolutionarily conserved SREBP inhibition by RhoA and acto-
myosin contraction. In humans, a total of 124 proteins (including
isoforms), corresponding to 75 genes12,13, are predicted to be
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geranylgeranylated by GGTase1. To identify geranylgeranylated
proteins involved in SREBP1 regulation, we assembled a custom
library of siRNAs targeting all but one (PALM3) of the mRNAs
coding for proteins predicted to be GGTase1 targets. Next, we
screened this library in MDA-MB-231 cells, in condition of basal
SREBP activity (medium supplemented with 10% Fetal Bovine
Serum, FBS), using a LDLR-Luc-based SREBP1 activation assay. As
shown in Fig. 2a, the majority of transfected siRNAs led to SREBP
activation. Of note, many of the targeted proteins, whose down-
regulation by siRNA was able to activate SREBP1, were involved in
actin cytoskeleton dynamics (Supplementary Fig. 2a). Among these
proteins, RhoA, a small GTPase known to control acto-myosin
dynamics, scored as second best hit in the screening (Fig. 2a and
Supplementary Table 3) and the first one after validation of the top
five hits using independent siRNAs and LDLR-Luc or SCD1-Luc
reporter (Supplementary Fig. 2b–d)14. This evidence led us to
hypothesise that RhoA could act as a negative regulator of SREBP1
and lipid biosynthesis. We next evaluated the level of RhoA pre-
nylation in cells in which statin treatment inhibited mevalonate
pathway, leading to SREBP1 activation. In these conditions, a
reduction of RhoA prenylation correlated with the activation of
SREBP1 (Fig. 2c), while addition of GGPP to the medium efficiently
rescued RhoA prenylation (Fig. 2c). This suggested that RhoA
activation might play a role on SREBP1 regulation. Confirming this
hypothesis, silencing of RhoA by two independent siRNAs (Sup-
plementary Fig. 2b) caused SREBP1 maturation and functional
activation, as assessed by SCD1 protein accumulation (Fig. 2b) and
either LDLR-Luc or SCD1-Luc reporter activity (Supplementary
Fig. 2c, d). Conversely, overexpression of a constitutively active
form of RhoA, RhoA G14V (Supplementary Fig. 2g), caused a
reduction of LDLR-Luc (Fig. 2d and Supplementary Fig. 2h) signal
and SCD1-Luc (Supplementary Fig. 2i), while overexpression of the
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Fig. 1 Protein geranylgeranylation regulates SREBP1. a Low density lipoprotein receptor promoter-luciferase (LDLR-Luc) assay in MCF-10A cells. Medium
containing 5% horse serum (HS, as control) was replaced with 5% HS medium supplemented with 10 μM cerivastatin (STATIN), serum-free medium
(SFM) or 2% lipid serum (lipid-depleted serum, LDS) medium, for 24 h. Cells were either mock-treated, or treated with cholesterol (CHOL), geranylgeranyl
pyrophosphate (GGPP) or farnesyl pyrophosphate (FPP). b RT-qPCR quantification of LDLR, SCD1, ACC1 and FASN gene expression in MCF-10A cells.
c Western blot analysis of MCF-10A cells. d LDLR-Luc assay in MCF-10A cells. 5% HS medium (control) was replaced with medium supplemented with
2% LDS and 1 μM cerivastatin (STATIN), and increasing doses of GGPP (20, 40 and 100 μM) for 24 h. e Scheme of geranylgeranyl (GG) conjugation to
cysteine. f LDLR-Luc assay in MCF-10A cells treated with DMSO as control or geranylgeranyl pyrophosphate transferase I inhibitor (GGTI-298). Cells
transfected with the mutated construct LDLR-Luc MUT underwent the same treatments. gWestern blot analysis of MCF-10A cells treated with GGTI-298
for the indicated time (hours, h). h RT-qPCR quantification of LDLR, SCD1, ACC1 and FASN gene expression in MCF-10A cells treated with DMSO as control
or GGTI-298. i Western blot analysis of MCF-10A cells transfected with control (siCTL) SREBP1 (siBP1) and SREBP2 (siBP2) siRNAs and treated with
GGTI-298 for 24 h. j BODIPY 493/503 staining of lipid droplets (in red) in Mahlavu cells treated with GGTI-298. Nuclei were stained with HOECHST
(in blue). Scale bar, 15 μm. Graph bars represent mean ± s.d. of n= 3 biological replicates. Values in (a, b and f) are expressed as Relative Luminometer
Units (RLU). Values in (b and h) are expressed as mRNA levels relative to control. In (b, c) 5% HS medium (control) was replaced with SFM or SFM
supplemented with GGPP for 24 h. For western blots, ACTIN was used as loading control, mSREBP indicates mature protein. Blots and images are
representative of n= 3 biological replicates. P value: *P < 0.05, **P < 0.01, ***P < 0.001 by two-tailed Student’s t-test for all analyses
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dominant negative RhoA T19N (Supplementary Fig. 2g) caused
LDLR-Luc (Fig. 2d and Supplementary Fig. 2h) and SCD1-Luc
activation (Supplementary Fig. 2i). Accordingly, RhoA inhibition by
C3 toxin caused LDLR-Luc (Fig. 2e and Supplementary Fig. 2j) and
SCD1-Luc activation (Supplementary Fig. 2k) and induction of
LDLR, SCD1 and HMGCR mRNA expression (Supplementary
Fig. 2l).
Upon geranylgeranylation, RhoA localizes at the plasma
membrane and triggers actin polymerisation and acto-myosin
contraction, via activation of its downstream effector Rho-kinase
(ROCK)15, which phosphorylates the myosin light chain 2
(MLC2). To test whether the regulation of SREBP1 by RhoA
requires the canonical ROCK pathway, we treated human
epithelial breast cells with either the ROCK inhibitor Y-27632
or the myosin inhibitor Blebbistatin and monitored SREBP1
transcriptional activity. Both treatments activated SREBP1, as
shown by induction of either LDLR-Luc (Fig. 2f and Supple-
mentary Fig. 2j) or SCD1-Luc reporter activity (Supplementary
Fig. 2k), and by LDLR, SCD1, ACC1, FASN and HMGCR mRNA
expression (Supplementary Fig. 2l). Moreover, the effect of RhoA
overexpression on SREBP1 activation was abolished by inhibition
of actin polymerisation with Latrunculin A treatment (Fig. 2d and
Supplementary Fig. 2h, i), thus demonstrating that actin
polymerisation acts downstream of RhoA/ROCK signalling to
control SREBP1 activation. Furthermore, inhibition of either
RhoA or ROCK induced a massive accumulation of lipid droplets
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Fig. 2 RhoA and acto-myosin regulate the activity of hSREBP1 and dSREBP. a Screening of low density lipoprotein receptor promoter-luciferase activity in
MDA-MB-231 cells transfected with constructs expressing firefly (LDLR-Luc) and renilla (Rluc) luciferase and either control siRNA (siCTL) or siRNAs
targeting genes encoding geranylgeranyl pyrophosphate transferase I (GGTase1) protein substrates. bWestern blot analysis of MDA-MB-231 and Mahlavu
cells 48 h after transfection with siCTL or RhoA targeting siRNAs (siR#1 and siR#2). Hsp90 was used as loading control. mSREBP indicates mature protein.
c Western blot analyses of immunoprecipitated (IP) RhoA in MCF-10A cells treated DMSO (as control), 1 μM cerivastatin (STAT), 1 μM cerivastatin and
20 μM GGPP (STAT+GGPP), 5 μM GGTI-298 or 5 μM FTI-277. IgGs were used as IP control. d LDLR-Luc assay in MCF-10A cells 12 h after transfection
with pcDNA3-GFP control plasmid, pcDNA3-GFP-RhoA G14V construct with a 6 h DMSO treatment, pcDNA3-GFP-RhoA G14V construct with a 6 h
Latrunculin A (G14V + Lat.A) treatment, or pcDNA3-GFP-RhoA T19N construct. e LDLR-Luc assay in MCF-10A cells treated with either DMSO as control
or C3 for 24 h. f LDLR-Luc assay in MCF-10A cells treated with either DMSO as control, Y-27632, or Blebbistatin (Blebbist.) for 24 h. g BODIPY 493/
503 staining of lipid droplets (in red) in Mahlavu cells treated with either DMSO, C3 or Y-27632 for 24 h. Scale bar, 15 μm. h, i BODIPY 493/503 staining
of lipid droplets (in red) and immunofluorescence analysis of dSREBP (in green) and phosphorylated myosin light chain (pMLC2, in magenta) in Drosophila
larval fat body from h flies expressing either Luciferase or dRhoA RNAi, or dRhoA RNAi and treated with fatostatin (FTS) and i wild-type flies treated with
either DMSO or Y-27632. Scale bar, 20 μm. Graphs bars in (c–f) represent mean ± s.d. of n= 3 biological replicates. Values in (d–f) are expressed as
Relative Luminometer Units (RLU). Nuclei in (h–i) were stained with HOECHST (in blue). Blots and images are representative of n= 3 biological replicates.
P value: *P < 0.05, **P < 0.01, ***P < 0.001 by two-tailed Student’s t-test for all analyses
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in liver cells (Fig. 2g). Taken together, these experiments show
that RhoA/ROCK signalling and acto-myosin dynamics impact
on SREBP1 activation and lipid biosynthesis in human cells.
We further investigated the impact of the ROCK/acto-myosin
axis on SREBP activity, by using Drosophila melanogaster as
a model organism, taking advantage that it expresses a single
SREBP homologue (dSREBP)4 whose activity is controlled
independently of cholesterol16,17. dSREBP turned out to be
activated in Drosophila S2 cells maintained for 24 h in serum-free
medium. This effect was prevented by supplementing the
medium with GGPP (Supplementary Fig. 3a). Moreover,
inhibition of either actin polymerisation or acto-myosin contrac-
tion, with Latrunculin A or the ROCK inhibitor Y-27632,
respectively, caused activation of dSREBP to an extent similar
to maintaining cells in lipid-depleted medium16 (Supplementary
Fig. 3b), thus demonstrating that the ROCK/acto-myosin axis
controls SREBP maturation in Drosophila cells. We next validated
these findings in vivo, by monitoring dSREBP activation and lipid
accumulation in the larval adipose tissue (fat body)18, upon either
tissue-specific knockdown of Drosophila RhoA (dRhoA), or
inhibition of ROCK by Y-2763219,20. dRhoA knockdown and
ROCK inhibition impaired acto-myosin contractility in adipo-
cytes, as demonstrated by reduced staining of phosphorylated
MLC2 (pMLC2) (Fig. 2h, i). Strikingly, both conditions promoted
dSREBP maturation (Supplementary Fig. 3c, d), nuclear translo-
cation (Fig. 2h, i) and transcriptional activity in these cells, as
shown by upregulation of mRNA levels of the dSREBP target
Fatty Acid Synthase (FAS) (Supplementary Fig. 3e) and expansion
of LDs (Fig. 2h, i and Supplementary Fig. 3f, g). Treatment with
fatostatin, a potent SREBP1 inhibitor21, suppressed both
phenotypes induced by dRhoA knockdown, i.e. FAS upregulation
(Supplementary Fig. 3e) and lipid accumulation (Fig. 2h),
demonstrating that these effects were the result of dSREBP
activity.
Altogether, these experiments demonstrate that modulation of
acto-myosin dynamics impacts on dSREBP activation and lipid
biosynthesis and accumulation in a living organism.
ECM stiffening inhibits SREBP-dependent lipid biosynthesis.
Acto-myosin contractility has a key role in intracellular sensing
and transduction of mechanical forces generated by the archi-
tecture and rigidity of the ECM. The physical properties of the
ECM influence the growth and shape of virtually all tissues and
organs22, and impact on a plethora of processes ranging from
tissue morphogenesis to cancer development. Physical cues are
promptly sensed by acto-myosin through RhoA22. Therefore, we
hypothesized that the physical features of the ECM could impact
on SREBP1 activation via RhoA. We tested this hypothesis by
growing human epithelial breast cells on fibronectin-coated
hydrogels characterized by progressively reduced elastic moduli
(e.g. 50, 4 and 0.5 kPa; Fig. 3a). In these conditions, ECM soft-
ening led to a marked impairment of mechano-signalling path-
ways, as demonstrated by reduction of phosphorylated MLC2
(pMLC2) and Focal Adhesion Kinase (pFAK), as well as of the
protein levels of the mechano-transducer TAZ (Fig. 3b, e), and
triggered a progressive induction of SREBP1 protein maturation
(Fig. 3b, e) and transcriptional activity (Fig. 3c, d and Supple-
mentary Fig. 4a, b). Furthermore, cells grown in soft ECM
showed a marked SREBP1-dependent lipid droplets accumulation
(Fig. 3d, f and Supplementary Fig. 4b). In line with these data,
unbiased gene set enrichment analysis showed that the genes
involved in lipid metabolism were enriched in MDA-MB-231
cells grown on soft as compared to cells grown on stiff hydrogels
(Supplementary Fig. 4c)23. Using the same culturing conditions,
the impact of mechanical stimuli on SREBP1 cleavage and activity
was further confirmed in primary cells from mouse mammary
and liver epithelia, and in cell lines from different human tissue
origin (i.e. liver, colon, breast, pancreas and others). Indeed, along
with reduced pMLC2 and TAZ protein levels, all the cells grown
on soft conditions exhibited an increased maturation of SREBP1
and, an enhancement of its transcriptional activity, as demon-
strated by increased SCD1 protein levels (Supplementary Fig. 4d).
Taken together, these results demonstrate that SREBP1 activity
is under control of mechanical cues and that increase of ECM
stiffness may inhibit its biological function.
To validate our observations in human samples, we generated a
signature specific for SREBP124 (Supplementary Table 4), as a
proxy of SREBP1 activation, to interrogate two public datasets of
human transcriptional profiles from different physiological and
pathological conditions: (i) normal breast tissue with high vs low
mammographic density25, a parameter that directly correlates
with tissue stiffness26; (ii) lung tissue from patients affected by
Idiopathic Pulmonary Fibrosis, a condition linked to pulmonary
tissue stiffness27, vs healthy controls28. Of note, activation of
SREBP1 inversely correlated with mammographic density and
lung tissue fibrosis, suggesting that in these physio-pathological
conditions SREBP1 might respond to mechanical cues (Fig. 3g).
AMPK suppresses SREBP1 activation downstream of mechanical
inputs. We next investigated how mechanical stimuli and acto-
myosin dynamics control SREBP1 activation. SREBP1 maturation,
stability, nuclear accumulation and transcriptional activity are
controlled by a complex repertoire of PTMs29–32. Among them,
phosphorylation by AMP-activated protein kinase (AMPK), a key
sensor of the cellular energy status, inhibits SREBP1 proteolytic
maturation29. AMPK has been recently found to be activated by
E-cadherin-dependent actin polymerisation33 and by mechan-
osensitive Ca2+ influx at focal adhesions34. Therefore, we reasoned
that, in response to an increase in ECM stiffness, acto-myosin
contraction leads to AMPK activation and consequent SREBP1
inhibition, as a mechanism to prevent anabolic processes and
increase ATP availability. Consistently, in human breast epithelial
cells, inhibition of RhoA/ROCK by either siRNA, treatment with
different drugs (C3 and Y-27632), or soft ECM culture conditions,
suppressed AMPK activation, as demonstrated by reduced phos-
phorylation of its activation loop (pThr172) and its target protein
Acetyl-CoA Carboxylase (ACC1, Fig. 4a–c). Importantly, in human
epithelial breast cells either treated with Y-27632 or grown on soft
ECM, reactivation of AMPK by AICAR, an AMP analogue known
to activate AMPK, inhibited SREBP1 maturation, SCD1 transcrip-
tional induction and lipid droplet accumulation (Fig. 4d–f), indi-
cating that AMPK mediates the effects of mechanical forces on
SREBP1.These data demonstrate that AMPK coordinates SREBP1
activation and lipid biosynthesis downstream of environmental
mechanical cues
SREBP1 drives mechano-dependent MSC adipogenic com-
mitment. Based on our evidence, it is conceivable that, through
this mechanism, soft substrates could promote adipogenesis by
unleashing SREBP1 activity upon inhibition of acto-myosin
contraction35,36. This could be the case of MSCs. Indeed, adult
MSCs are known to spontaneously differentiate into adipocytes or
osteoblasts when cultured on a soft or stiff matrix, respectively37,38.
However, the mechanisms by which a soft microenvironment
instructs MSCs to undergo adipogenesis are largely unknown. To
test our hypothesis, we cultured mMSCs on either stiff or soft
fibronectin-coated hydrogels, or we treated mMSCs cultured in
stiff matrix with Y-27632. In these conditions, we monitored adi-
pogenesis by evaluating mRNA levels of the adipogenesis markers
Pparg, AdipoQ, Fabp4 and Cebpa (Fig. 5a, d) and by Oil-Red-O
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staining (Fig. 5b, e). As expected, adipogenesis was significantly
induced by ECM softening (Fig. 5a, b) or by ROCK inhibition in
stiff substrates (Fig. 5d, e), thus confirming a key role of ECM
rigidity in MSC fate determination. Importantly, in mMSCs grown
on soft ECM or treated with the ROCK inhibitor, AMPK activity
was reduced and SREBP1 was strongly activated (Fig. 5c, f), while
SREBP1 pharmacological inhibition by fatostatin (Fig. 5c, f) pre-
vented MSC differentiation into adipocytes (Fig. 5a, b, d, e). These
results demonstrate that SREBP1 in response to mechanical cues
drives adipogenic specification of MSCs.
Discussion
In this work, we highlighted a cholesterol-independent feedback
mechanism of SREBP1 regulation, mediated by geranylgeranyl
pyrophosphate. This isoprenoid is a mevalonate-derived metabolite
exerting crucial functions in regulating cell homoeostasis, mainly
through protein geranylgeranylation. Geranylgeranylation of several
Rho-GTPases is required to coordinate acto-myosin dynamics in
response to chemical and physical stimuli. We demonstrated that
prenylation of RhoA strongly inhibits SREBP1 activity, thus
establishing a crucial role of SREBP1 as a transducer of environ-
mental mechanical cues and unveiling a link between the physical
properties of the ECM and lipid metabolism. SREBP1 inhibition
exerted by RhoA turned out to be conserved from invertebrates to
humans, and it may represent a fundamental mechanism to reg-
ulate cell behaviour. Supporting this notion, we showed that
SREBP1 activation determines the fate of MSCs in response to
mechanical cues.
Furthermore, we found that acto-myosin contractility regulates
Drosophila fat storage via SREBP-dependent lipid biosynthesis and
accumulation, supporting that coordination between mechanical
and metabolic pathways may have implications at the organismal
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Fig. 3 SREBP1 is under the control of mechanical cues. a Scheme of cell (in green) adhesion to fibronectin-coated hydrogel matrix (in blue) with 50 and
0.5 kPa elastic modulus. b Western blot analysis of MCF-10A cells cultured on fibronectin-coated hydrogel matrix of high (50 kPa elastic modulus),
intermediate (4 kPa elastic modulus) or low (0.5 kPa elastic modulus) stiffness, for 24 h. c Low density lipoprotein receptor promoter-luciferase
(LDLR-Luc) assay in MCF-10A cells cultured on stiff (50 kPa elastic modulus, as control) or soft (0.5 kPa elastic modulus) fibronectin-coated hydrogel
matrix for 24 h. d RT-qPCR quantification of the expression of the indicated genes in MCF-10A cells cultured on stiff (50 kPa elastic modulus, as control) or
soft (0.5 kPa elastic modulus) fibronectin-coated hydrogel matrix, or soft (0.5 kPa elastic modulus) fibronectin-coated hydrogel matrix with fatostatin
treatment (FTS), for 24 h. eWestern blot analysis of primary cultures of hepatocytes and mammary epithelial cells on stiff (50 kPa elastic modulus) or soft
(0.5 kPa elastic modulus) fibronectin-coated hydrogel matrix for 24 h. f BODIPY 493/503 staining of lipid droplets (in red) in Mahlavu cells cultured on
stiff (50 kPa elastic modulus, as control, in black) or soft (0.5 kPa elastic modulus, in red) fibronectin-coated hydrogel matrix, or soft (0.5 kPa elastic
modulus) fibronectin-coated hydrogel matrix with fatostatin treatment (FTS, in blue), for 24 h. Nuclei were stained with HOECHST (in blue). Scale bar,
10 μm. g Average standardized expression levels of SREBP1 signature in human samples datasets of normal breast tissue with high vs low mammographic
density (MD) and Idiopathic Pulmonary Fibrosis (IPF) patients vs healthy controls. Graphs bars represent mean ± s.d. of n= 3 biological replicates. P value:
*P < 0.05 by two-tailed Student’s t-test (c, d) and two-way ANOVA (g). For western blots, Hsp90 was used as loading control, mSREBP indicates mature
protein. Blots and images are representative of n= 3 biological replicates
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level such as in human physio-pathologic conditions, which is
shown by our results (Fig. 3g) in breast and lung tissues with altered
ECM deposition and stiffening. In other diseases, as in cancer, this
homoeostatic interplay might be overcome at multiple levels.
Indeed, diverse oncogenic proteins have been shown to be activated
and stabilized upon ECM stiffening and, in turn, to directly engage
key metabolic transducers to boost cancer cell proliferation23,39–41.
Acto-myosin dynamics has been estimated to drain an important
fraction of cellular energy42, and it has been recently proposed to
stimulate glucose uptake and ATP production via AMPK43, as well
as to foster glycolysis via the release of aldolase A from actin
fibres44. Our finding that SREBP1-dependent lipid anabolism is
prevented by cytoskeleton contraction via activation of AMPK
suggests that this mechanism could be important to integrate
environmental mechanical signals with intracellular requirements,
allowing a cell to maintain an optimal energy status.
Methods
Cell lines. MCF-10A cells are a human immortalized normal epithelial breast cell
line and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)/F12
(LONZA) (1:1) supplemented with 5% Horse Serum (HS), 100 U/mL penicillin and
10 μg/mL streptomycin, 20 ng/ml recombinant human epidermal growth factor
(EGF), 10 µg/ml recombinant human insulin and 500 ng/ml hydrocortisone.
MDA-MB-231 are a human breast cancer cell line. IHH are immortalized human
hepatocytes. Mahlavu are human hepatocellular carcinoma cells. HT29 are human
colorectal adenocarcinoma cells. U87MG and U251 are human glioblastoma cells.
U2OS are a human osteosarcoma cells line. H1299 are a human non-small cell lung
cancer cell line. PANC-1 are a human pancreatic adenocarcinoma cell line.
U87MG and U251 are glioblastoma cell lines. HT29, MDA-MB-231, PANC-1,
U2OS, U87MG and U251 cells were cultured in DMEM (LONZA) supplemented
with 10% Foetal Bovine Serum (FBS) 100 U/mL penicillin and 10 μg/mL strepto-
mycin. Mahlavu cells were cultured in Eagle’s Minimum Essential Medium
(EMEM, Sigma) supplemented with FBS, 100 U/mL penicillin, 10 μg/mL strepto-
mycin, 1% Minimum Essential Medium Non-Essential Amino Acids (MEM
NEAA) and 1% Glutamax. IHH cells were cultured in DMEM/F12 (LONZA) (1:1)
supplemented with 10% FBS, 100 U/mL penicillin and 10 μg/mL streptomycin,
5 µg/ml recombinant human insulin, 1 µg/ml hydrocortisone and 1% Glutamax.
H1299 cells were cultured in RPMI 1640 supplemented with 10% FBS, 100 U/mL
penicillin and 10 μg/mL streptomycin.
Primary mouse mammary epithelial cells were cultured in DMEM supplemented
with 10% FBS, 100 U/mL penicillin and 10 μg/mL streptomycin, 20 ng/ml
recombinant human EGF, 10 µg/ml recombinant human insulin, 500 ng/ml
hydrocortisone. Primary hepatocytes were cultured in DMEM supplemented with
10% FBS, 100 U/mL penicillin, 10 μg/mL streptomycin, 1% glutamine, 6 μg/ml
insulin and 1 μM dexamethasone.
Human cell lines are from ATCC or other laboratories cooperating on the
project. Drosophila melanogaster Schneider’s 2 (S2) cell line was a kind gift from F.
Feiguin, International Centre for Genetic Engineering and Biotechnology (ICGEB),
Trieste.
Cells were subjected to STR genotyping with PowerPlex 18D System and
confirmed in their identity comparing the results to reference cell databases
(DMSZ, ATCC and JCRB databases).
Cells were tested for mycoplasma contamination with negative results.
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Preparation of fibronectin-coated hydrogel matrix. 50, 4 or 0.5 kPa Easy Coat
hydrogels (Cell guidance system) were coated with 10 μg/ml fibronectin.
Reagents and plasmids. The following compounds and working concentration
were used: AICAR (1mM, Sigma Aldrich A9978), Blebbistatin (50 μM Sigma Aldrich
B0560), Cerivastatin (1 μM Sigma Aldrich SML0005), Cholesterol (0.5 mM, Sigma
Aldrich C8667), Farnesyl Pyrophosphate (20 μM, Sigma Aldrich F6892), Fatostatin
hydrocloryde (20 μM, Sigma Aldrich F8932), Fibronectin (10 μg/ml, Sigma Aldrich
F0895), GGTI-298 (5 μM, Sigma Aldrich G5169), Geranylgeranyl Pyrophosphate
(20 μM, Sigma Aldrich G6025), Y-27632 (20 μM, Sigma Aldrich Y0503). Latrunculin
A (0.5 μM, Santa Cruz Biotechnologies sc-202691) and C3 (100 ng/ml, Cytoskeleton
CT04). DMSO was purchased from Sigma Aldrich (D4540). Lipoprotein Depleted
Serum was purchased from Biowest (S181L). Treatments lasted 24 h unless otherwise
stated.
pEGFP–RhoA-G14V was a gift from C. Schneider (Laboratorio Nazionale CIB,
Italy). pcDNA3-EGFP-RhoA-T19N (Addgene plasmid #12967) was a gift from
Gary Bokoch. The pLDLR-Luc construct (also known as pES7, Addgene plasmids
#14940), harbouring the SREBP-responsive Sterol Responsive Element (SRE)
sequence (ATCACCCCAC), and the pLDLR-Luc mutSRE construct (LDLR-Luc
MUT, Addgene plasmid #14945), harbouring a SREBP-unresponsive mutant SRE
(ATAACCCCAC)11 were gifts from Axel Nohturfft. The pGL3-SCD1-Luc
construct was generated by cloning a PCR amplified DNA fragment corresponding
to nucleotides −405 to −229 of the human SCD1 gene into the pGL3 vector with
KpnI and BglII restriction enzymes.
Transfections. siRNA transfections were performed with Lipofectamine RNAi-
MAX (Life technologies) in antibiotic-free medium according to manufacturer
instructions. Sequences of siRNAs are reported in Supplementary Table 1. Control
siRNA was AllStars negative control Qiagen 1027281. Plasmid DNA transfections
of MDA-MB-231 and MCF-10A cells were performed with LTX (Invitrogen) in
antibiotic-free medium according to the manufacturer instructions.
Luciferase assay. pLDLR-Luc (300 ng/cm2), pLDLR-Luc mutSRE (300 ng/cm2)11,
and pGL3-SCD1-Luc reporters (300 ng/cm2) were co-transfected with the
CMV–Renilla construct (30 ng/cm2), 12 h after transfection with either siRNAs,
pcDNA3 (100 ng/cm2), pcDNA3–GFP-RhoA-G14V (100 ng/cm2) or pcDNA3-
GFP-RhoA-T19N plasmids (100 ng/cm2). Luciferase/Renilla signal was analysed in
cell lysates, 24 h after transfection of luciferase reporters, using the Dual-Luciferase
Reporter Assay System (Promega E1910).
Quantitative RT-PCR. Cells were harvested in Qiazol lyses reagent (Qiagen) for
total RNA extraction, and contaminant DNA was removed by DNase treatment.
Quantitative real time PCR analyses were carried out on cDNAs retrotranscribed
with iScript™ Advanced cDNA Synthesis Kit (Biorad 172-5038) and analysed with
BIORAD CFX96 TouchTM detection system and Biorad CFX Manager software.
Quantitative analysis was performed by the 2-ΔΔCt method. Histone 3 was used as
reference gene. PCR primer sequences are reported in Supplementary Table 2.
Antibodies. The following antibodies and working concentrations were used: anti-
Actin C11 (1:5000, Sigma Aldrich A2066, for western blot), anti-SREBP1 2A4
(1:500, Santa Cruz Biotechnology sc13551, for western blot), anti-SREBP1 H160
(1:100, Santa Cruz Biotechnology sc8984, for immunofluorescence), anti-SREBP2
(1:500, BD Bioscience 557037, for western blot), anti-SCD1 (1:1000, Abcam
ab19862, for western blot), anti-GAPDH (6C5) (1:5000, Santa Cruz Biotechnology
sc32233, for western blot), anti-AMPK (1:1000, Cell Signalling 2532S, for western
blot), anti-AMPK phospho Thr172 (1:1000, Cell Signalling 2531S, for western
blot), anti-ACC1 (1:1000, Cell Signalling 3676S, for western blot), anti-ACC1
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Fig. 5 SREBP1 regulates mesenchymal stem cell commitment upon cytoskeleton remodelling. a RT-qPCR quantification of the indicated genes in mouse
mesenchymal stem cells (mMSCs) cultured on stiff (50 kPa elastic modulus, as control) or soft (0.5 kPa elastic modulus) fibronectin-coated hydrogel
matrix, or soft (0.5 kPa elastic modulus) fibronectin-coated hydrogel matrix with fatostatin treatment (FTS). Values are expressed as mRNA levels relative
to control. b Oil-Red-O staining of lipid droplets (in red) in mMSCs cultured on either stiff (50 kPa elastic modulus) or soft (0.5 kPa elastic modulus)
fibronectin-coated hydrogel matrix, or soft (0.5 kPa elastic modulus) fibronectin-coated hydrogel matrix with fatostatin treatment (FTS). Scale bar, 100 μm.
cWestern blot analysis of mMSCs cultured on either stiff (50 kPa elastic modulus) or soft (0.5 kPa elastic modulus) fibronectin-coated hydrogel matrix, or
soft (0.5 kPa elastic modulus) fibronectin-coated hydrogel matrix with fatostatin treatment (FTS). d RT-qPCR quantification of the indicated genes in
mMSCs cultured in differentiating medium and treated with either DMSO as control, or with Y-27632, or Y-27632 and fatostatin (Y-27632 + FTS). Values
are expressed as mRNA levels relative to control. e Oil-Red-O staining of lipid droplets (in red) in mMSCs cultured in differentiating medium and treated
with DMSO as control, or with Y-27632 or Y-27632 and fatostatin (Y-27632+FTS). Medium composition is detailed in the Methods section. Scale bar,
100 μm. f Western blot analysis of mMSC cultured in differentiating medium and treated with either DMSO as control or with Y-27632, or Y-27632 and
fatostatin (FTS). Graph bars represent mean ± s.d. of n= 3 biological replicates. For western blots, Hsp90 was used as loading control, mSREBP indicates
mature protein. P value: *P < 0.05, ***P < 0.001 by two-tailed paired Student’s t-test. Blots and images are representative of n= 3 biological replicates
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phospho Ser79 (1:1000, (Cell Signalling 11818S, for western blot), anti-Farnesyl
(1:1000, AB4073 Merck Millipore), anti-Hsp90 (1:2000, Santa Cruz Biotechnology
sc13119, for western blot), anti-MLC2 (1:1000, Cell Signalling 3675S, for western
blot), anti-MLC2 phospho Ser19 (1:500, Cell Signalling 3671S, for western blot and
immunofluorescence), anti-FAK C-20 (1:1000, Santa Cruz Biotechnology sc-558,
for western blot) and anti-FAK phospho Y397 (1:1000, Abcam ab81298, for wes-
tern blot).
Targeted RNAi screening. Seventy four siRNAs targeting all mRNAs coding for
human proteins predicted to be GGTI targets (Supplementary Table 3) were
cherry-picked robotically from a human genome-wide siRNA library (siGENOME
SMARTPool; pools of four siRNAs per gene, Dharmacon) and arrayed in 384-well
white plates (PerkinElmer). For the screening experiments, MDA-MB-231 cells
were transfected with the targeted siRNA library, using a standard reverse trans-
fection protocol45. Briefly, the transfection reagent (Lipofectamine RNAiMAX; Life
Technologies) was diluted in OPTI-MEM (Life Technologies) and added to the
siRNAs arrayed on the 384-well plates; 30 min later, the cells were suspended in
culture medium without antibiotics and seeded (2.0 × 103 per well). Twenty-four
hours after siRNA transfection, cells were transfected with the LDLR-Luc reporter
(Firefly), together with a plasmid expressing Renilla luciferase for normalization,
using FuGENE HD Transfection Reagent (Promega) diluted in OPTI-MEM; the
transfection mix (10 µl per well) was added to cells using a Multidrop Combi
Reagent Dispenser (Thermo Fisher Scientific). Forty-eight hours after transfection
of the reporter (i.e. 72 h after siRNA transfection), the cells were lysed in 1 × Glo
Lysis Buffer (Promega); Firefly and Renilla luciferase activities were measured using
the Dual-Glo Luciferase Assay System (Promega), according to the manufacturer’s
instructions, using an Envision Multimode Plate Reader (PerkinElmer). Normal-
ized LDLR reporter activity was calculated as fold change over a control non-
targeting siRNA.
Western blot analysis of mammalian and Drosophila S2 cells. For immuno-
blotting analyses protein were lysed in Lysis Buffer (NP40 1%, Tris-HCL pH= 8
50 mM, NaCl 150 mM, EDTA 1mM) solution, supplemented with protease and
phosphatase inhibitors. Lysates were loaded and separated in SDS-PAGE, followed
by western blotting on Nitrocellulose membranes (Amersham). Blocking was
performed in Blotto-tween (PBS, 0.2% Tween-20, not fat dry milk 5%) or with
TBST (0.2% Tween-20, Tris/HCl 25 mM pH 7.5) plus 5% BSA (PanReac Appli-
chem) depending on the antibody.
Immunoprecipitation. Immunoprecipitation (IP) experiments were performed
using IP buffer (NaCl 120 mM, Tris-HCl pH8 20 mM, EDTA 1mM, NP40 0,5%)
with protease inhibitors. Samples were sonicated three times and cleared by cen-
trifugation for 10 min at 13,000 × g at 4 °C and incubated for 4 h at 4 °C with anti-
RhoA or IgG antibodies. After 1 h incubation with protein G-Sepharose (GE
Healthcare), immunoprecipitates were washed three times in IP buffer, resus-
pended in sample buffer and analyzed by immunoblotting.
Immunofluorescence analysis of mammalian cells. Briefly, cells were fixed in 4%
paraformaldehyde for 10 min, washed in phosphate buffered saline (PBS), per-
meabilized with 0.1% Triton X-100 for 10 min and blocked in 3% FBS/PBS for
30 min. Antigen recognition was done by incubation with primary antibody at 4 °C
for 14 h and with secondary antibodies (goat anti-mouse Alexa Fluor 568 and goat
anti-rabbit Alexa Fluor 488, Life Technologies) at 4 °C for 2 h. Nuclei were stained
with Hoechst 33342 (Life Technologies) for 15 min.
BODIPY staining of mammalian cells. Cells were fixed in 4% paraformaldehyde
for 15 min, stained with 0.1 μg/ml BODIPY-493/503 at 37 °C for 30 min and DAPI
at 25 °C for 15 min. Cells were imaged using a Nikon Ti-E inverted fluorescence
microscope.
Drosophila cell lines. Drosophila melanogaster Schneider’s 2 (S2) line cells are
macrophage-like cells of embryonic origin (kind gift from F. Feiguin, International
Centre for Genetic Engineering and Biotechnology, Trieste) and were cultured in
Insect-XPRESS medium (LONZA 12-730) supplemented with heat-inactivated
10% FBS, 100 U/mL penicillin and 10 μg/mL streptomycin, at 25 °C.
Drosophila lines and housing. The following Drosophila lines were used: w1118
(as wild-type control, kind gift of F. Feiguin, International Centre for Genetic
Engineering and Biotechnology, Trieste, Italy), w1118;UAS-dRhoARNAi/CyO-GFP
(generated from line VDRC#12734, Vienna Drosophila Resource Center), w1118;cg-
Gal4 (Bloomington Drosophila Stock Center BDSC#7011, kind gift of P. Bellosta,
University of Trento, Italy) and w1118;UAS-LuciferaseRNAi (Bloomington Droso-
phila Stock Center BDSC#35788, kind gift of B. Mollereau, Ecole Normale
Superierure de Lyon, France). The genotype of larvae analysed in Figs. 2h and 3c, e,
f was: w1118;cg-Gal4;UAS-LuciferaseRNAi (Luc RNAi) and w1118;cg-Gal4/UAS-
dRhoARNAi (dRhoA RNAi). Flies were maintained at 25 °C on standard corn/yeast
medium.
Dissection and culture of Drosophila larval fat bodies. Fat bodies were dissected
from N= 6 third instar female larvae in PBS and either immediately processed or
cultured for 14 h in Insect-XPRESS medium (LONZA 12-730) supplemented
with heat-inactivated 10% FBS, 100 U/mL penicillin, 10 μg/mL streptomycin and
10 μg/ml Insulin and drug (Y-27632, Fatostatin or AICAR) or drug solvent
(according to the manufacturer instructions).
Western blot analysis of Drosophila fat bodies. Fat bodies freshly dissected in
PBS and cultured fat bodies washed in PBS were transferred in lyses buffer and
processed for western blot analysis according to the protocol described for mam-
malian and Drosophila S2 cells.
Whole mount fluorescence staining of Drosophila fat bodies. Drosophila tissues
were stained according to a standard whole mount protocol46,47. Briefly, fat bodies
freshly dissected in PBS and cultured fat bodies washed in PBS were fixed in 4%
paraformaldehyde for 10min, rinsed three times in PBS for 5 min, permeabilized
with 0.1% Triton X-100/PBS for 10 min, and rinsed three times in PBS for 5 min, at
25 °C. Tissues were then incubated with primary antibodies for 14 h at 4 °C, washed
three times in PBS for 5 min, incubated with Alexa Fluor secondary antibodies (488,
568, 594, 647, Thermofisher, 1:400 dilution) at 25 °C for 2 h, and with 0.1 μg/ml
BODIPY-493/503 at 25 °C for 20min to stain lipid droplets. After rinsing three
times in PBS for 5 min, tissues were incubated with Hoechst 33342 (Life Tech-
nologies) and sealed onto glass slides in Prolong mounting medium. Images were
acquired with a Nikon ECLIPSE C1si confocal microscope and processed with
Nikon NIS-Elements Imaging Software for quantification of lipid droplets (Confocal
microscopy facility, University of Trieste). The mean size of lipid droplets was
quantified according to Bi and others work48 in images from N= 6 individuals.
Isolation of mouse mammary epithelial cells. Mammary glands from 8 to
12-week-old virgin female mice were enzymatically digested and single cell sus-
pensions of purified mammary epithelial cells (MECs) were obtained following a
standard protocol49. Briefly, mammary glands were digested at 37 °C for 1–2 h in
Epi-Cult-B medium (Stem Cell Technologies Inc) with 600 U/ml collagenase
(Sigma Aldrich) and 200 U/ml hyaluronidase (Sigma Aldrich). After lysis of the red
blood cells with NH4Cl, the remaining cells were washed with PBS/0.02% w/v
EDTA. Cells were then dissociated with 0.25% w/v trypsin, 0.2% w/v EDTA for 2
min by gentle pipetting, then incubated in 5 mg/ml Dispase II (Sigma Aldrich) plus
1 μg/ml DNase I (Sigma Aldrich) for 5 min, followed by filtration through a 40 μM
cell strainer (BD Falcon). MECs were then purified using the EasySep Mouse
Mammary Stem Cell Enrichment Kit (Stem Cell Technologies Inc). MECs were
seeded on top of 50 or 0.5 kPa Easy Coat hydrogels (Cell guidance system) coated
with 10 μg/ml fibronectin and harvested after 24 h.
Primary hepatocytes isolation. Briefly, livers were removed quickly from
euthanized mice and the tissue was finely minced with scissors and washed several
times with HBSS to remove blood clots. After a last wash with HBSS, the sample
was transferred to a falcon with a collagenase solution (0.25 mg/ml Collagenase D
in HBSS-Hepes buffer) and was incubated for 45 min at 37 °C in a rotating
incubator. At the end of the incubation 10 ml of HBSS containing 5% FBS was
added. The cell suspension was filtrated through a 70-μm cell strainer (BD Falcon)
and centrifuged at 50 × g for 5 min at 4 °C. The supernatant was discarded, and
fresh medium was added. Isolated cells were then seeded on top of 50 kPa or 0.5
kPa Easy Coat hydrogels (Cell guidance system) coated with 10 μg/ml fibronectin
and harvested after 24 h.
Isolation of mouse mesenchymal stem cells. Mouse mesenchymal stem cells
(mMSCs) were isolated from 12-week-old. Mice were anaesthetised, sacrificed
and the femurs were harvested. After isolation and cleaning, the marrow was
flushed from the bones using 26-gauge needle and 3 mL syringe into complete
PBS with 2% FBS and 1 mM EDTA. Cells were gently resuspended and further
purified with the EasySep mouse MSC isolation kit (Stem cell 19771), following
manufacturer instructions. Viable cells were subsequently resuspended in a
growth medium (non-differentiating medium) consisting of DMEM (LONZA),
15% FBS (Euroclone), 2 mM Glutamine, 100 U/mL penicillin and 10 μg/mL
streptomycin. Cells were then seeded on cell culture dishes and placed at 37 °C
20% O2. The culture medium was replaced every 2 days until reaching 80%
confluence (2 days).
Differentiation of mouse mesenchymal stem cells in culture. For spontaneous
differentiation on soft matrix, mMSCs were seeded in non-differentiating medium
on 50 or 0.5 kPa Easy Coat hydrogels (Cell guidance system) fibronectin-coated
hydrogels until reaching 80% confluence (2 days). Then they were cultured in fresh
non-differentiating medium or fresh non-differentiating medium supplemented
with fatostatin, for 5 days. Cells were then fixed in 4% paraformaldehyde, stained
with Oil-Red-O (Sigma Aldrich), rinsed three times with deionised H2O and
imaged. For pharmacological induction of adipogenic differentiation on stiff
matrix, mMSCs were seeded in non-differentiating medium on plastic culture
dishes (Euroclone) until reaching 80% confluence (2 days). Then they were
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cultured in either non-differentiating medium, or differentiating medium, con-
sisting of DMEM (LONZA) supplemented with 15% FBS (Euroclone), penicillin
100 U/mL, streptomycin 10 μg/mL, 500 μM 3-isobutyl-1-methylxanthine (Sigma
Aldrich), 1 μM dexamethasone (Sigma Aldrich) and 10 μg/ml insulin (Sigma
Aldrich), for 3 days. During this period, DMSO, Y-27632 and fatostatin were added
daily to differentiating medium. Then, cells were maintained with DMEM, 15%
FBS, penicillin 100 U/mL, streptomycin 10 μg/mL, 1 mM glutamine and 10 μg/ml
insulin. After seven days, cells were then fixed in 4% paraformaldehyde, stained
with Oil-Red-O (Sigma Aldrich) and rinsed three times with deionised H2O and
imaged.
Animal care. The mice were housed and used in a specific pathogen-free (SPF)
animal facility. Procedures involving animals and their care were performed in
conformity with institutional guidelines (D.L. 116/92 and subsequent com-
plementing circulars).
Analysis of microarray data. To investigate gene set differentially enriched upon
plating on matrixes with different stiffness, we compared the expression profiles
of MDA-MB-231 breast cancer cells plated on a stiff substrate (plastic) with the
same cells plated on a soft substrate (hydrogels 0.5 kPa). Raw gene expression
data were downloaded from Gene Expression Omnibus GSE9352923. All data
analyses were performed in R (version 3.2.4) using Bioconductor libraries (BioC
3.2) and R statistical packages. Probe level signals were converted to expression
values using the robust multi-array average procedure RMA of the Bioconductor
affy package. Functional enrichment was performed using Gene Set Enrichment
Analysis (http://www.broadinstitute.org/gsea/index.jsp) and gene sets of the
Molecular Signature Database (http://software.broadinstitute.org/gsea/msigdb/
index.jsp). In particular, we investigated whether the expression levels of MDA-
MB-231 cells grown on a soft substrate were associated with elevated expression
of the 674 Reactome gene sets. GSEA software was applied on log2 expression
data of MDA-MB-231 cells cultured on stiff and soft substrates. Gene sets were
considered significantly enriched at FDR < 5% when using Signal2Noise as
metric and 1000 permutations of gene sets. The dot plot in Supplementary Fig. 4
was generated using the ggplot2 R package (v.2.2.1, https://cran.r-project.org/
web/packages/ggplot2/index.html).
Analysis of human sample datasets. To generate a specific SREBP1 tran-
scriptional signature, we selected genes altered in SREBP1 knock-in and SCAP
knockout, but not SREBP2-knockin mice24. We then compiled a list of the 16
human orthologues of those genes using the DIOPT-DRSC Integrative Ortholog
Prediction Tool50. We fetched the following datasets from the NCBI GEO
database: GSE99621 (from Luzina et al., 2018)28 and GSE49175 (from Sun et al.,
2013)25. GSE49175 data were downloaded from the sample table matching each
entry, and the log2(mean sample signal/mean signal in reference control) was
used as the expression value for each probe. For GSE49175, RNA-seq raw reads
were fetched by the NCBI SRA fastq tool51 and uploaded to the Galaxy web
platform, using the public server at usegalaxy.org52 for analysis. The quality of
the reads was assessed by the FastQC tool53. The reads were de-interlaced with
the FastQ de-interlacer tool54 and subsequently trimmed using the Trimmo-
matic55 with an IlluminaClip step to remove the matching adapter sequences
and a sliding-window following step, averaging across 4 bases and requiring
average quality of 20. We then used HISAT256 to align the reads on the
GRChg38 reference human genome in an unstranded manner. Aligned reads
were subsequently filtered with SAMtools57, keeping only aligned reads with
minimum MAPQ quality score of 20 and mapped in a proper pair. Aligned reads
were counted using featureCounts58. Raw data counts were subjected to the
Variance Stabilizing Transformation from the DeSeq2 R package (R Develop-
ment core team, 2008)59 to obtain normally distributed data for further analyses.
The obtained expression data for both datasets were processed by a combined
score with zero mean transformation, and the average expression of the
SREBP1 signature was calculated averaging the z-score of all the genes in the list.
The average value was used as a measure of SREBP1 signature expression.
Statistical significance was calculated on the single z-score for all the genes in the
signature using a two-way ANOVA test (GraphPad Prism v.7).
Statistics and reproducibility. All the experiments are representative of at least
three independent repeats. Graph bars represent mean ± s.d. from n= 3 biological
replicates. All P values were determined using two-tailed Student’s t-test, with a
95% confidence threshold as indicated in figure legends.
Data availability
All data supporting the findings of this study are available from the corresponding author
on reasonable request.
Received: 6 August 2018 Accepted: 25 February 2019
References
1. Horton, J. D., Goldstein, J. L. & Brown, M. S. Critical review SREBPs:
activators of the complete program of cholesterol and fatty acid synthesis in
the liver. J. Clin. Invest. 109, 1125–1131 (2002).
2. Shimano, H. & Sato, R. SREBP-regulated lipid metabolism: convergent
physiology—divergent pathophysiology. Nat. Rev. Endocrinol. 13, 710–730
(2017).
3. Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol
metabolism by proteolysis of a membrane-bound transcription factor. Cell 89,
331–340 (1997).
4. Osborne, T. F. & Espenshade, P. J. Evolutionary conservation and adaptation
in the mechanism that regulates SREBP action: What a long, strange tRIP it’s
been. Genes Dev. 23, 2578–2591 (2009).
5. Hannah, V. C., Ou, J., Luong, A., Goldstein, J. L. & Brown, M. S. Unsaturated
fatty acids downregulate SREBP isoforms 1a and 1c by two mechanisms in
HEK-293 Cells. J. Biol. Chem. 276, 4365–4372 (2001).
6. Liao, J. K. Isoprenoids as mediators of the biological effects of statins. J. Clin.
Investig. 110, 285–288 (2002).
7. Edwards, P. & Ericsson, J. Sterols and isoprenoids: signaling molecules derived
from the cholesterol biosynthetic pathway. Annu. Rev. Biochem. 68, 157–185
(1999).
8. Clendening, J. W. et al. Dysregulation of the mevalonate pathway promotes
transformation. Proc. Natl Acad. Sci. USA 107, 15051–15056 (2010).
9. Sorrentino, G. et al. Metabolic control of YAP and TAZ by the mevalonate
pathway. Nat. Cell Biol. 16, 357–366 (2014).
10. Eckert, G. P. et al. Regulation of the brain isoprenoids farnesyl- and
geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol.
Dis. 35, 251–257 (2009).
11. Castoreno, A. B. et al. Transcriptional regulation of phagocytosis-induced
membrane biogenesis by sterol regulatory element binding proteins. Proc. Natl
Acad. Sci. USA 102, 13129–13134 (2005).
12. Maurer-Stroh, S. et al. Towards complete sets of farnesylated and
geranylgeranylated proteins. PLoS Comput. Biol. 3, 634–648 (2007).
13. Maurer-Stroh, S. & Eisenhaber, F. Refinement and prediction of protein
prenylation motifs. Genome Biol. 6, R55 (2005).
14. Allal, C. et al. RhoA prenylation is required for promotion of cell growth and
transformation and cytoskeleton organization but not for induction of serum
response element transcription. J. Biol. Chem. 275, 31001–31008 (2000).
15. Amano, M., Nakayama, M. & Kaibuchi, K. Rho-kinase/ROCK: A key
regulator of the cytoskeleton and cell polarity. Cytoskeleton 67, 545–554
(2010).
16. Seegmiller, A. C. et al. The SREBP pathway in Drosophila: regulation by
palmitate, not sterols. Dev. Cell. 2, 229–238 (2002).
17. Dobrosotskaya, I. Y., Seegmiller, A. C., Brown, M. S., Goldstein, J. L. &
Rawson, R. B. Regulation of SREBP processing and membrane lipid
production by phospholipids in Drosophila. Science 296, 879–883 (2002).
18. Ballard, S. L., Jarolimova, J. & Wharton, K. A. Gbb/BMP signaling is required
to maintain energy homeostasis in Drosophila. Dev. Biol. 337, 375–385 (2010).
19. Mizuno, T., Amano, M., Kaibuchi, K. & Nishida, Y. Identification and
characterization of Drosophila homolog of Rho-kinase. Gene 238, 437–444
(1999).
20. Winter, C. G. et al. Drosophila Rho-associated kinase (Drok) links Frizzled-
mediated planar cell polarity signaling to the actin cytoskeleton. Cell 105,
81–91 (2001).
21. Kamisuki, S. et al. A small molecule that blocks fat synthesis by inhibiting the
activation of SREBP. Chem. Biol. 16, 882–892 (2009).
22. Seong, J., Wang, N. & Wang, Y. Mechanotransduction at focal adhesions:
from physiology to cancer development. J. Cell. Mol. Med. 17, 597–604 (2013).
23. Ingallina, E. et al. Mechanical cues control mutant p53 stability through a
mevalonate-RhoA axis. Nat. Cell Biol. 20, 28–35 (2018).
24. Horton, J. D. et al. Combined analysis of oligonucleotide microarray data from
transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl
Acad. Sci. USA 100, 12027–12032 (2003).
25. Sun, X. et al. Relationship of mammographic density and gene expression:
analysis of normal breast tissue surrounding breast cancer. Clin. Cancer Res.
19, 4972–4982 (2013).
26. Boyd, N. F. et al. Mammographic features associated with interval breast
cancers in screening programs. Breast Cancer Res. 16, 417 (2014).
27. Liu, F. et al. Mechanosignaling through YAP and TAZ drives fibroblast
activation and fibrosis. Am. J. Physiol. Cell. Mol. Physiol. 308, L344–L357
(2015).
28. Luzina, I. G. et al. Transcriptomic evidence of immune activation in
macroscopically normal-appearing and scarred lung tissues in idiopathic
pulmonary fibrosis. Cell. Immunol. 325, 1–13 (2018).
29. Li, Y. et al. AMPK phosphorylates and inhibits SREBP activity to attenuate
hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice.
Cell. Metab. 13, 376–388 (2011).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09152-7
10 NATURE COMMUNICATIONS |         (2019) 10:1326 | https://doi.org/10.1038/s41467-019-09152-7 | www.nature.com/naturecommunications
30. Sundqvist, A. et al. Control of lipid metabolism by phosphorylation-
dependent degradation of the SREBP family of transcription factors by
SCFFbw7. Cell. Metab. 1, 379–391 (2005).
31. Ponugoti, B. et al. SIRT1 deacetylates and inhibits SREBP-1C activity in
regulation of hepatic lipid metabolism. J. Biol. Chem. 285, 33959–33970
(2010).
32. Hirano, Y., Murata, S., Tanaka, K., Shimizu, M. & Sato, R. Sterol regulatory
element-binding proteins are negatively regulated through SUMO-1
modification independent of the ubiquitin/26 S proteasome pathway. J. Biol.
Chem. 278, 16809–16819 (2003).
33. Bays, J. L., Campbell, H. K., Heidema, C., Sebbagh, M. & Demali, K. A.
Linking E-cadherin mechanotransduction to cell metabolism through force-
mediated activation of AMPK. Nat. Cell Biol. 19, 724–731 (2017).
34. Tojkander, S., Ciuba, K. & Lappalainen, P. CaMKK2 regulates
mechanosensitive assembly of contractile actin stress fibers. Cell Rep. 24,
11–19 (2018).
35. Kim, J. B. & Spiegelman, B. M. ADD1/SREBP1 promotes adipocyte
differentiation and gene expression linked to fatty acid metabolism. Genes
Dev. 10, 1096–1107 (1996).
36. Fajas, L. et al. Regulation of peroxisome proliferator-activated receptor γ
expression by adipocyte differentiation and determination factor 1/sterol
regulatory element binding protein 1: implications for adipocyte
differentiation and metabolism. Mol. Cell. Biol. 19, 5495–5503 (1999).
37. Engler, A. J., Sen, S., Sweeney, H. L. & Discher, D. E. Matrix elasticity directs
stem cell lineage specification. Cell 126, 677–689 (2006).
38. McBeath, R., Pirone, D. M., Nelson, C. M., Bhadriraju, K. & Chen, C. S. Cell
shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment.
Dev. Cell. 6, 483–495 (2004).
39. Freed-Pastor, W. A. et al. Mutant p53 disrupts mammary tissue architecture
via the mevalonate pathway. Cell 148, 244–258 (2012).
40. Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. Nature 474,
179–183 (2011).
41. Paszek, M. J. et al. Tensional homeostasis and the malignant phenotype.
Cancer Cell. 8, 241–254 (2005).
42. Bernstein, B. W. & Bamburg, J. R. Actin-ATP hydrolysis is a major energy
drain for neurons. J. Neurosci. 23, 1–6 (2003).
43. Vu, V., Bui, P., Eguchi, M., Xu, A. & Sweeney, G. Globular adiponectin
induces LKB1/AMPK-dependent glucose uptake via actin cytoskeleton
remodeling. J. Mol. Endocrinol. 51, 155–165 (2013).
44. Hu, H. et al. Phosphoinositide 3-kinase regulates glycolysis through
mobilization of aldolase from the actin cytoskeleton. Cell 164, 433–446
(2016).
45. Mano, M., Ippodrino, R., Zentilin, L., Zacchigna, S. & Giacca, M. Genome-
wide RNAi screening identifies host restriction factors critical for in vivo AAV
transduction. Proc. Natl Acad. Sci. 112, 11276–11281 (2015).
46. Napoletano, F. et al. P53-dependent programmed necrosis controls germ cell
homeostasis during spermatogenesis. PLoS Genetics 13, e1007024 (2017).
47. Van Den Brink, D. M. et al. Physiological and pathological roles of FATP-
mediated lipid droplets in Drosophila and mice retina. PLoS Genet. 14,
e1007627 (2018).
48. Bi, J. et al. Seipin promotes adipose tissue fat storage through the ER Ca2+
-ATPase SERCA. Cell. Metab. 19, 861–871 (2014).
49. Rustighi, A. et al. Prolyl-isomerase Pin 1 controls normal and cancer stem
cells of the breast. EMBO Mol. Med. 6, 99–119 (2014).
50. Hu, Y. et al. An integrative approach to ortholog prediction for disease-
focused and other functional studies. BMC Bioinforma. 12, 357 (2011).
51. Leinonen, R., Sugawara, H. & Shumway, M., International Nucleotide
Sequence Database Collaboration. The sequence read archive. Nucleic Acids
Res. 39, D19–D21 (2011).
52. Afgan, E. et al. The Galaxy platform for accessible, reproducible and
collaborative biomedical analyses: 2016 update. Nucleic Acids Res. 44,
W3–W10 (2016).
53. Andrews, S. FastQC A quality control tool for high throughput sequence data.
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/. Accessed 11 Dec
2018.
54. Blankenberg, D. et al. Manipulation of FASTQ data with Galaxy.
Bioinformatics 26, 1783–1785 (2010).
55. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for
Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
56. Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low
memory requirements. Nat. Methods 12, 357–360 (2015).
57. Li, H. et al. The Sequence Alignment/Map format and SAMtools.
Bioinformatics 25, 2078–2079 (2009).
58. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose
program for assigning sequence reads to genomic features. Bioinformatics 30,
923–930 (2014).
59. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Acknowledgements
We thank A. Testa for discussions and proofreading the manuscript. We acknowledge G.
Pastore for technical support. We acknowledge support by the Italian Health Ministry
(RF-2011-02346976 to G.D.S.), the Italian University and Research Ministry (PRIN-
2015-8KZKE3), the Cariplo Foundation (grant no. 2014-0812), Beneficentia-Stiftung, the
European Regional Development Fund Interreg Italia-Österreich (PreCanMed
ITAT1009), Fondazione CRTrieste and Regione Autonoma Friuli Venezia Giulia
(Contributo ex art. 15 L.R. 17/2014) to G.D.S. This work was supported by grants from
the Associazione Italiana per la Ricerca sul Cancro (AIRC) and AIRC Special Program
Molecular Clinical Oncology ‘5 per mille’ (grant no. 10016) to G.D.S. and S.B., and AIRC
IG (grant no. 17659) to G.D.S. M.M. was supported by the FCT Investigator Programme
IF/00694/2013 from the Portuguese Foundation for Science and Technology (FCT),
Portugal. G.S. is a recipient of a FEBS long-term fellowship. R.B. and M.F. are supported
by a FIRC-AIRC fellowship for Italy. F.N. was supported by a European Union FP7/
Associazione Italiana per la Ricerca sul Cancro (AIRC) Reintegration Grant (iCARE N°
17885) and a University of Trieste FRA 2018 Starting Grant. We thank the Confocal
microscopy facility of the University of Trieste. We also thank F. Feiguin (International
Centre for Genetic Engineering and Biotechnology, Trieste, Italy) for providing Droso-
phila cells and lines, and the Vienna Drosophila Resource Center, the Bloomington
Drosophila Stock Center, P. Bellosta (University of Trento, Italy), and B. Mollereau
(Ecole Normale Superierure de Lyon, France) for providing Drosophila lines.
Author contributions
G.S. and G.D.S. conceived the study. R.B., A.Z., M.F. and G.S. performed the experi-
ments. F.N. and R.B. performed Drosophila experiments. M.M. performed the high-
content screening. M.F. and S.B. performed bioinformatic analysis. S.M.-S. performed
bioinformatics prediction of GGTase1 targets. G.S., R.B., F.N. and G.D.S. designed
experiments. G.S., R.B., F.N. and G.D.S. wrote the manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-09152-7.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks John Shyy, Jin Ye and
the other anonymous reviewer(s) for their contribution to the peer review of this work.
Peer reviewer reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09152-7 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1326 | https://doi.org/10.1038/s41467-019-09152-7 | www.nature.com/naturecommunications 11
